Mechanisms of psilocybin on the treatment of posttraumatic stress disorder. - Choi C; Johnson DE; Chen-Li D; Rosenblat J (Journal of psychopharmacology (Oxford, England), 2026)

Anxiety and Affective Symptoms Related to the Use of Classic Psychedelics: A Systematic Review. - Viljoen G; Betzler F (Current topics in behavioral neurosciences, 2026)

Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trials. - Aghajanian S; Shafiee A; Parvizi Omran S; Rezaei Nejad A; Jafarabady K; Kohandel Gargari O; Rajai S; Mohammadi I; Bahrami Babaheidari T; Bakhtiyari M (Journal of psychopharmacology (Oxford, England), 2026)

Masking Influences: A Systematic Review of Placebo Control and Masking in Psychedelic Studies. - Barstowe A; Kajonius PJ (Journal of psychoactive drugs, 2026)

Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use. - Syed OA; Petranker R; Fewster EC; Sobolenko V; Beidas Z; Husain MI; Lake S; Lucas P (Journal of psychoactive drugs, 2026)

Psychedelics as an intervention for psychological, existential distress in terminally ill patients: A systematic review and network meta-analysis. - Marchi M; Farina R; Rachedi K; Laonigro F; Žuljević MF; Pingani L; Ferrari S; Somers M; Boks MPM; Galeazzi GM (Journal of psychopharmacology (Oxford, England), 2026)

Informed Consent in Psychedelic-Assisted Therapy. - Bradberry MM; Appelbaum PS; Gukasyan N (Current topics in behavioral neurosciences, 2026)

Development of Psilocybe Mushroom Species Reference Material-Cultivation Parameters and Chemical Profiles. - Windsor C; Kreynes AE; Chilton JS; Chioffi WA; Niebergall C; Dodds K (Journal of AOAC International, 2026)

Attitudes Toward Psychedelic Treatments by Individuals With Histories of Substance Use or Psychiatric Disorders: A Survey Study. - Prostko S; Wu A; Maddams S; Szpak V; Rosenblum N; Hilt LM; Suzuki J (Journal of addiction medicine, 2026)

Toward Standardized Products Containing Biomass of Psilocybe Cubensis Fungi. - Foster K; Morrison I; Daniel S; Antoine J; Thankappan B; De La Haye W; Tyler M; Grant C; Delgoda R (Journal of AOAC International, 2026)

Building standards of psychedelic care: Qualitative examination of expert perspectives on safety, inclusion, and accountability. - Chwyl C; Wilson-Poe AR; Hoffman KA; Bazinet A; Pertl K; Luoma JB; des Jarlais D; Bielavitz S; Korthuis PT (The International journal on drug policy, 2026)

Pharmacological characterisation of psilocybin and 5-MeO-DMT discriminative cues in the rat and their translational value for identifying novel psychedelics. - Higgins GA; MacMillan C; de Lannoy I; Tyler C; Slassi M (Journal of psychopharmacology (Oxford, England), 2026)

Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial. - McGowan NM; Rucker JJ; Yehuda R; Agrawal M; Modlin NL; Simmons H; Tofil-Kaluza A; Das S; Goodwin GM (Journal of psychopharmacology (Oxford, England), 2026)

Psychedelic Drug Checking: Analytical and Strategic Challenges in Harm Reduction for Classic Psychedelics. - Hirschfeld T; Blei F; Stegemann L; van der Gouwe D; Smit-Rigter L (Current topics in behavioral neurosciences, 2026)

Mind the gap! Addressing unresolved aspects of abuse potential evaluation and scheduling of classic and novel psychedelic drugs. - Heal DJ; Gosden J; Smith SL (Journal of psychopharmacology (Oxford, England), 2026)

A novel psychedelic 5-HT receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer. - Marek GJ; Makai-Bölöni S; Umbricht D; Christian EP; Winters J; Dvorak D; Raines S; Hughes ZA; Austin EW; Klein AK; Leong W; Krol FJ; et al. (Journal of psychopharmacology (Oxford, England), 2026)

Psilocybin Outside the Clinic: Public Health Challenges of Increasing Publicity, Accessibility, and Use. - Hutchison KE; Hooper JF; Karoly HC (JAMA psychiatry, 2026)

'Magic' mechanisms underlie psilocybin's effects in chronic pain. - Lewis S (Nature reviews. Neuroscience, 2026)

Effects of psychedelic microdosing on cognitive functions: A systematic review and meta-analysis. - Pinhas N; Eidlman N; Barnea A; Peled-Avron L (Neuroscience and biobehavioral reviews, 2026)

Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety. - Konstantinou GN; Rosenblat J; Hales S; Husain MI; Blumberger DM (General hospital psychiatry, 2026)

Psilocybin-assisted therapy for individuals with palliative care needs: A systematic review of safety and efficacy. - Matos ARS; Silva AC; Rego L; Fernandes R; Gonçalves S (Palliative medicine, 2026)

Stepping back into life: How Psychedelic Assisted Psychotherapy transforms the way of life of the terminally ill. - Dwyer J; Johnston RB; O'Callaghan C; Ross M (General hospital psychiatry, 2026)

Perceptions of Psilocybin-Assisted Psychotherapy and Standard Interventions for Nicotine Cessation. - Kamilar-Britt P; Oliva AB; Earleywine M (Journal of psychoactive drugs, 2026)

An exploration of the relationships between the effects of psilocybin on behavior, 5-HT receptor occupancy, and neuroplastic effects in mice. - Maltby CJ; Klein AK; Paschen E; Pinto J; Dvorak D; Hedde JR; Hanks AN; Bianchi M; Hughes ZA (Journal of psychopharmacology (Oxford, England), 2026)

The Effect of Magic Mushroom (Psilocybe azurescens) on Social Interaction, Anxiety- and Depressive-Like Behaviors in Male Rats; the Role of Neuroinflammation, Oxidative Stress, and Neurotrophic Factors. - Moghadam H; Akbari P; Beirami E; Nabavifard S; Ameli A; Valian N (Journal of neuroscience research, 2026)

Advancing treatment paradigms: the role of psilocybin in managing major depressive disorder. - Rasheed S; Arif R; Raza AA; Samadi A (Annals of medicine and surgery (2012), 2026)

Pharmacological Management of Anxiety in End-of-Life Care: A Systematic Review of Benzodiazepines, Opioids, and Psilocybin. - Freitas da Costa B; Hartmann P; Pagnin D (Human psychopharmacology, 2026)

Indigenous Knowledge Systems & Psychedelic Science: Towards Ethical and Reciprocal Collaboration. - Magar V; Robbins M; Fernández Lobo Blanco ÓML; Ali IL; Anderson B; Grob C; Henningfield JE; Kryskow P; Kuiper H; Loizaga-Velder A; Rush B; Volat M; et al. (Journal of psychopharmacology (Oxford, England), 2026)

Single-dose psilocybin promotes cell-type-specific changes of neurons in the orbitofrontal cortex. - Huang Z; Wei X; Wang Y; Tian J; Dong J; Liang B; Lu L; Zhang W (Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics, 2026)

Magic mushrooms and mood: Exploring psilocybin as a depression treatment. - Rasool M; Hannan TM; Imam M (JPMA. The Journal of the Pakistan Medical Association, 2026)

Psychedelic-Related Psychosis: From Model Psychosis to Psychotherapy. - Bröcker AL; Majić T; Montag C (Current topics in behavioral neurosciences, 2026)

Classifying Psychedelic-Related Complications. - Majić T; Gouzoulis-Mayfrank E; Evens R (Current topics in behavioral neurosciences, 2026)

Contextualizing Violence Risk Associated With Hallucinogens. - Durns T; Iannuzzi G (Focus (American Psychiatric Publishing), 2026)

New Antidepressant Development in the Treatment of Depression. - Spiti A; Caldirola D; Perna G (Advances in experimental medicine and biology, 2026)

Psychedelics: Future Therapeutics in Major Depression? - Olivier B; Olivier JDA (Advances in experimental medicine and biology, 2026)

Rural-Urban Disparities in Access to Interventional Psychiatry Treatments among VA Patients. - Shiner B; DuFort V; Peltzman T; Watts BV (Rural mental health, 2026)

﻿Systematic study of (, ) sensu lato and psilocybin-producing traits of species from China. - He MQ; Yang WQ; Phurbu D; Liu F; Li JX; Cao B; Zhao RL (IMA fungus, 2026)

A Promise Without Panacea: Psychedelic-Assisted Therapies in Modern Psychiatry. - Raza M; Kaur J (Cureus, 2026)

The Use of Psilocybin in the Treatment of Depressive Disorders: A Narrative Review. - Siwek L; Nowocien M; Balajewicz B; Samborska A; Szukalska S; Karczewska M; Lichwala K; Wróblewski K; Wróblewska P (Cureus, 2026)

Retraction: Acute psilocybin increased cortical activities in rats. - Frontiers Editorial Office (Frontiers in neuroscience, 2026)

The potential of event-related beta oscillations as biomarkers for neuromodulatory treatment efficacy. - Habelt B (Frontiers in psychology, 2026)

The Relationship Between Participant Pretreatment Clinical Presentation and the Quality of Psilocybin Experience: A Retrospective Analysis. - Kirlić N; Atli M; Mistry S; Gold M; Goodwin GM (Journal of clinical psychopharmacology, 2026)

5 Years of bipolar disorder conversations on Reddit: Methods, key topics and future directions. - Poh C; Head C; Nunez JJ; Lapadat L; Morton E; Collaborative RESearch Team to Study Psychosocial Issues in Bipolar Disorder (CREST.BD); Michalak EE (PloS one, 2026)

Psychedelic therapy and postpartum depression: priorities and prospects. - Thuery G; Crossen F; Mc Loone D; Hinds C; Duffy R; Jairaj C; Harkin A; Kelly JR (Therapeutic advances in psychopharmacology, 2026)

Editorial: Psychedelic-assisted psychotherapies: from clinical trials to credibility. - Evans M; Charrette A (Frontiers in neuroscience, 2026)

Psychedelic exposure in pregnancy: a scoping review to inform perinatal drug safety and clinical counseling. - Albert OM; Arthur A (Therapeutic advances in drug safety, 2026)

Psychedelics and the quantum brain: a falsifiable hypothesis on Posner molecules and spin-dependent pharmacology. - Geraci J; Viirre E; Qorri B; Pani L (Frontiers in pharmacology, 2026)

The Effect of on Spatial Memory and BDNF Expression in Male Rats Exposed to Chronic Unpredictable Mild Stress. - Ghaffarzadegan R; Karimi M; Hedayatjoo B; Behnoud H; Jasemi E; Mohammadi M; Roustaei S; Razmi A; Vaseghi S (Journal of psychoactive drugs, 2026)

Preferences, Perceptions, and Environmental Considerations of Natural and Synthetic Psychedelic Substances: Findings from the Global Psychedelic Survey. - Syed OA; Petranker R; Fewster EC; Sobolenko V; Beidas Z; Husain MI; Lake S; Lucas P (Journal of psychoactive drugs, 2026)

Correction: Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020-2021. - Abramsky-Sze S; Marseille E; Matzopoulos R; Morlock R; Lerer L (Frontiers in psychiatry, 2026)

Metastability of resting-state bold fMRI as a reliable biomarker of individual brain dynamics: An interrogation of within-subject variability as a function of total acquisition time. - Sheheitli H; Hermosillo R; Grimsrud G; Madison T; Dominguez OM; Nelson S; Fair D; Nahas Z (Network neuroscience (Cambridge, Mass.), 2026)

Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians. - Beichmann K; Catzeflis P; Aicher HD; Seragnoli F; Calder A; Amrani A; Hasler G (Therapeutic advances in psychopharmacology, 2026)

Phylogenomic systematics of (Boletaceae) reveals cryptic diversity, resolves global evolutionary relationships, and suggests a novel psychoactive lineage. - Domnauer C; Dentinger BTM (Mycologia, 2026)

Marketing by online tobacco retailers: An observational cross-sectional study. - Apollonio DE; Dennehy CE; Tsourounis C; Wakefield T (Tobacco induced diseases, 2026)

Thirty Years of Ibogaine Research: A Literature Review on Clinical Perspectives. - Kervadec E; Bezo A; Serreau R; Strika-Bruneau L; Fauvel B; Amirouche A; Benyamina A; Romeo B (Journal of clinical psychopharmacology, 2026)

Psychedelics and neuroanesthesia: A narrative review of converging mechanisms - Kunal Kumar Sharma (Journal of Scientific Innovations in Anesthesiology, 2025)

Effects of Serotonergic Psychedelics on Synaptic Function and Neuroplasticity - Aneta Petrušková (OPUS FAU - Online publication system of Friedrich-Alexander-Universität Erlangen-Nürnberg, 2025)

Self-Transcendent Perceptual Dynamics and the Effects of Dispositional Mindfulness on Altered States of Consciousness: A Prospective Longitudinal Observational Study of a Naturalistic Psychedelic Retreat - Sebastian Ehmann; Nikoloz Mosahvili; Angela White; John Cuzzupe; Brooke Tompkins; Jodi McKibben; John J.B. Allen; Michael Gawrysiak (PsyArXiv, 2025)

A Randomized Double-blinded Controlled Trial for the Treatment of Persisting Symptoms After Concussion With Psilocybin-assisted Therapy: A Safety and Feasibility Trial - University of Calgary (ClinicalTrials.gov, 2025)

Microdosing Psychedelics to Improve Mood - Rotem Petranker (ClinicalTrials.gov, 2025)

Psilocybin as a Serotonergic Therapy in Epilepsy: Narrative Review of Therapeutic Potentials and Seizure Risks - Cervera-Sanchez MB; San-Juan D; Díaz-Peregrino R; Camacho-Castillo EZ; Bringas-Ortiz SA; Padilla-Cabezutd C. (Authorea Preprints, 2025)

Efficacy and Safety of Psychedelics in Mental Disorder Cases: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials. - Dominiak M; Gędek A; Modrzejewski S; Permoda-Pachuta A; Antosik AZ (Journal of clinical medicine, 2025)

Psilocybin decreases reward-seeking behavior accompanied by increased activity of parvalbumin neurons with perineuronal nets in the medial prefrontal cortex - Houff J; Williams A; Allen O; Gisabella B; Pantazopoulos H; Del Arco A. (bioRxiv, 2025)

Evolution and horizontal transfer of the psilocybin biosynthetic gene cluster drive the diversification of magic mushrooms - Fei Liu; Jiaxin Li; Wen-Qiang Yang; Mao-Qiang He; Bin Cao; Qi Wu; R. Cheewangkoon; Rui-Lin Zhao (Mycosphere, 2025)

A Systematic Review of the efficacy, safety, and Tolerability of Psychedelics in the Treatment of post-traumatic Stress Disorder - Manasicha Wongpaiboon; Jackson L. Shelton; Eric Delgado Rendon; Maddison Vail (Current Treatment Options in Psychiatry, 2025)

The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation - Sheppard Pratt Health System (ClinicalTrials.gov, 2025)

An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder - University of Chicago (ClinicalTrials.gov, 2025)

A Randomised, Triple-Blind, Dose-Finding Study of the Impact of Psilocybin on Motor Function in Healthy Participants - Bhagavan C; Carter O; Nielsen G; Berlowitz D; Issak S; Braat S; Zaloumis S; Attard Z; Oliver G; Mayne D; Rucker J; Butler M; et al. (medRxiv, 2025)

Allowing Similarities: Using Aldous Huxley’s Views on Mystical Experience to Assess the Import of Profound Unitive Experiences Occasioned by Psychedelic Substances - Dana W. Sawyer (Religions, 2025)

The genus Psilocybe in Italy - Giuseppe Venturella; Manuela Rollini; Giulia Mirabile; Nicola Favia; Maria Letizia Gargano (Italian Botanist, 2025)

Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter - NYU Langone Health (ClinicalTrials.gov, 2025)

Psilocybin modulates social behaviour in male and female mice in a time-dependent manner - Shadani S; McCoy K; Ong L; Greaves E; Conn K; Andrews ZB; Foldi CJ. (bioRxiv, 2025)

A Naturalistic Study on the Combined Neural and Psychological Effects of Psilocybin and Compassion Focused Imagery - Pallavicini C; Llobenes L; Cavanna F; de la Fuente LA; Muller S; Costa M; Gumiy N; Bruno N; D’Amelio T; Basran J; Plowright P; Stolkiner A; et al. (bioRxiv, 2025)

A qualitative analysis of participant expectations and experiences of psilocybin-assisted psychotherapy for methamphetamine use disorder. - Brett J; Lea T; Knock E; Albert S; Acheson L; Siefried KJ; Job S (Addiction (Abingdon, England), 2025)

The CAnadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT): A Multi-Phase Program Overview. - Carlson LE; Richardson H; Shore R; Albertyn CP; Balneaves LG; Bates A; Burnell M; Chochinov HM; Clements D; Deleemans J; Horlock H; Mathews J; et al. (Current oncology (Toronto, Ont.), 2025)

Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development. - Bukovsky D; Amaev A; Song J; Kyte S; Carmona-Torres E; Ueno F; Deluca V; Strafella AP; Husain MI; Graff-Guerrero A; Gerretsen P (Progress in neuro-psychopharmacology & biological psychiatry, 2025)

Cognitive outcomes following psilocybin-assisted therapy in treatment-resistant depression: A post-hoc analysis of a randomized, waitlist-controlled trial. - Johnson DE; Meshkat S; Kaczmarek ES; Rabin JS; Brudner RM; Chisamore N; Doyle Z; Bawks J; Riva-Cambrin J; Mansur RB; Lipsitz O; McIntyre RS; et al. (Progress in neuro-psychopharmacology & biological psychiatry, 2025)

From fungi to pharmacy: Applied technologies in psilocybin production and its therapeutic applications - Qinqing Chen; Peiyuan Chen; Tao Wei; Sunita Chamyuang; Bai-Xiong Chen (Creative Science, 2025)

Effects of LSD and Psilocybin on Heart Rate in Patients Receiving Psychedelic Treatment for Depressive and Anxiety Disorders: A Retrospective Observational Study - Mylène Cheng; Tatiana Aboulafia Brakha; Albert Buchard; Raya Anastasova; Léa Girani; Anna Breitenmoser; Sylvie Alaux; Cédric Mabilais; Caroline Amberger; Federico Seragnoli; Leonice Furtado; Gabriel Thorens; et al. (Psychology International, 2025)

Psilocybin Treatment as an Adjunct to Cognitive Behavioral Therapy for Eating Disorders: Therapeutic Rationale & Considerations for Protocol Development - Koning E; Gamberg S; Keshen A. (Preprints.org, 2025)

Wherefore the magic? The evolutionary role of psilocybin in nature - Matthews Nicholass K; Flis I; Hanley M; Knight M; Lane S; Littlejohn G; Thom M; Billington R; Boden R; Cummins R; Green B; Griffin C; et al. (bioRxiv, 2025)

Psilocybin reporting in media (PRiMe) for the treatment of depression. - Brar G; Burke T; Gribben AD; Harrington C; Thuery G; Kelly JR (Irish journal of psychological medicine, 2025)

Which Psychotherapy Model Should be Used in Psilocybin Treatment for Depression? - Koning E; Bacchi P; Chaves C; Gomes FA; Brietzke E (Trends in psychiatry and psychotherapy, 2025)

Preadministration of Lorazepam Negates the Long-Term Antidepressant-Like Effects of Psilocybin in Male Wistar Kyoto Rats - Sophie Woodruff; Meghan Hibicke; Charles D. Nichols (Psychedelic Medicine, 2025)

Psychedelic-Assisted Therapy (Pat): A New Frontier in Mental Health Treatment - M. H. M. Wickramasekara; G. D. M. C. Gonapaladeniya (The journal of desk research review and analysis., 2025)

Exploring Determinants of Psilocybin Acceptance as an Alternative Modality for Major Depressive Disorder: A Pilot Study - Shannon Antoine-Hardy; D’Elia Bonilla (Journal of Complementary and Alternative Medical Research, 2025)

The Role of Touch in Psychedelic Therapy: Perspectives From a Survey of Practitioners in Research Settings. - Bender DA; Nayak SM; Siegel JS; Hellerstein DJ; Ercal BC; Lenze EJ (American journal of psychotherapy, 2025)

Mapping psilocybin therapy: A systematic review of therapeutic frameworks, adaptations, and standardization across contemporary clinical trials. - Kittur ME; Burgos M LA; Jones BDM; Blumberger DM; Mulsant BH; Rosenblat JD; Husain MI (Journal of affective disorders, 2025)

Psilocybin-assisted psychotherapy for treatment-resistant obsessive-compulsive disorder: protocol for an open-label pilot study. - Ledwos N; Baer J; Husain MI; Blumberger DM; Patterson R; Hollingdrake E; Cheung E; Hawco C; Zrenner C; Zrenner B; Feusner JD; Rossell SL; et al. (BJPsych open, 2025)

The entropic brain today - Carhart-Harris R. (PsyArXiv, 2025)

The entropic brain today - Robin Carhart-Harris (PsyArXiv, 2025)

Psilocybin and MDMA in Couples Therapy: Investigating Treatment for Substance Use Disorders and Codependency - Samuel Hosford; Heather Austin-Robillard (Contemporary Family Therapy, 2025)

Engineering the Next Generation of Psychedelic Therapeutics through Serotonergic Precision and Pharmacokinetic Control. - Renner AC; Kargbo RB (ACS medicinal chemistry letters, 2025)

Age and cannabis co-use are associated with differences in experience and perceived benefits of psilocybin: a retrospective study - Jake Hooper; Sarah Williams; Raeghan Mueller; Kent Hutchison (PsyArXiv, 2025)

Real-World Psilocybin Therapy for Treatment-Resistant Depression: a Retrospective Observational Study - Jungwirth J; Westenhöfer S; Aicher H; Provaznikova B; Kronenberg G; Seifritz E; Prinz S; Olbrich S. (Research Square, 2025)

The Psychedelic Psilocin Suppresses Activity of Central Amygdala Corticotropin-Releasing Factor Receptor 1 Neurons and Decreases Ethanol Drinking in Female Mice - Magee Sarah N.; Sereno Allison C.; Echeveste-Sanchez Maria; Shannon Elizabeth G.; Mohsin Abir; Mott Sarah E.; Faccidomo Sara P.; Hodge Clyde W.; Herman Melissa A. (The Journal of Neuroscience, 2025)

Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacy: A Scoping Review - Suspène J; Huet S; Berteina-Raboin S; Benyamina A; Baril P; Morisset-Lopez S; Serreau R. (Qeios, 2025)

Unlocking the power of tryptamine alkaloids in Psilocybe fungi: chemistry, mental health potential and legal challenges - Mohammad Reza Mirzadeh; Khalid Moinuddin; Vasso Apostolopoulos; Caine Barlow; Jianhua Zhang (Mycological Progress, 2025)

Are Magic Mushrooms the Magic to Healing? - Wohlfarth; Gale; Hardy; Susan; Ray; Herman (DigitalCommons - Kennesaw State University (Kennesaw State University), 2025)

Investigating the Effects of a Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm Behaviour: an Experimental Medicine Study - Imperial College London (ClinicalTrials.gov, 2025)

Psychedelics as neuroplasticity enhancers: Mechanisms, therapeutic applications, and translational challenges - Taslim Uddin; Suma Akter; Kanak Yadab Ghosh (Advanced Neurology, 2025)

Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication in Patients With Chronic Pain: an Open-label Feasibility Study - University of British Columbia (ClinicalTrials.gov, 2025)

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer - NYU Langone Health (ClinicalTrials.gov, 2025)

Defining ‘psychedelic’ - Avery Ostrand; Matthew Nour; Christopher Timmermann; Andrea Rosati; Lisa Luan; Andrés Gómez-Emilsson; Julia Bornemann; Kyle Greenway; Leor Roseman; Robin Carhart-Harris (PsyArXiv, 2025)

Questioning the recovery of dissociated traumatic memories under psilocybin: comment on "Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa". - Kangaslampi S; Wolff M; Doss MK; Kloft-Heller L; Otgaar H (Journal of eating disorders, 2025)

Magic Mushrooms as Medicine: What the United States Can Learn from Jamaica’s Unregulated Psilocybin Industry as FDA Approval Nears - Spohn; Kyle (eYLS (Yale Law School), 2025)

Unexpected Detection of Psilocybin in a 100 mg Tramadol Tablet: A Forensic Case Report - Amin Reihani; Fatemeh Shaki (DOAJ (DOAJ: Directory of Open Access Journals), 2025)

Psychedelic Assisted Psychotherapy (PAP): the Geneva University Hospital model - F. Seragnoli (Emerging Trends in Drugs Addictions and Health, 2025)

Psilocybin and Neuroplasticity: Mechanisms, Therapeutic Potential, and Future Directions - S. Fereydouni (Emerging Trends in Drugs Addictions and Health, 2025)

Taking a Trip into Nature’s Medicine Cabinet: A Country Comparison of Efforts to Reschedule Psilocybin and MDMA for Therapeutic Use - Jones; Ariyah (eYLS (Yale Law School), 2025)

Psilocybin-assistierte Gruppenpsychotherapie bei Abhängigkeitserkrankungen - Wopfner; Alexander; Soravia; Leila M. (Open Access CRIS of the University of Bern, 2025)

Psychedelics for the Treatment of Substance Use Disorders - Johannes Klaus; Fritz Schneider; Rena Schaletzky; Daniel Sippel; Anil Batra (SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice, 2025)

Meaning and Purpose Therapy Modified for Psilocybin (P-MaP): A Treatment Model for Palliative Care Patients - Philip Garrity; Alicia Danforth; Brian Anderson; Jason M. Thompson (Journal of Health Service Psychology, 2025)

Three Cases of Depersonalization/Derealization Disorder Related to the Use of Classic Psychedelics - Dario Jalilzadeh Masah; Derin Marbin; Tomislav Majić (SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice, 2025)

Safety, feasibility, and tolerability of psilocybin in older adults with amnestic MCI: Preliminary data from a SV2a PET imaging study - Bukovsky D; Amaev A; Song J; Torres-Carmona E; Kyte S; Ueno F; Deluca V; Bowie C; Flint A; Husain I; Graff-Guerrero A; Gerretsen P. (Alzheimer's & dementia: the journal of the Alzheimer's Association, 2025)

Psilocybin Maintains Better Brain Function in an Alzheimer’s Disease Model with Reduced Neuroinflammation and Improved Hippocampal Neurogenesis - Madhu L; Somayaji Y; Kotian S; Attaluri S; Patel J; Panda P; Rao V; Kodali M; Shankar G; Rao S; Weintraub S; Shuai B; et al. (Alzheimer's & dementia: the journal of the Alzheimer's Association, 2025)

Limited prognostic value of early maladaptive schemas for acute psychedelic experience and symptom improvement - Buchard A; Seragnoli F; Sabe M; Eskinazi M; Aboulafia T; Furtado L; Briefer J; Roediger E; Penzenstadler L; Zullino D; Thorens G. (Research Square, 2025)

Real-World Effectiveness and Safety of Psychedelic-Assisted Psychotherapy: Outcomes from a Large-Scale Compassionate Use Cohort in Switzerland - Aboulafia-Brakha T; Buchard A; Mabilais C; Alaux S; Amberger C; Furtado L; Seragnoli F; Briefer J; Thorens G; Sabé M; Szczesniak L; Iuga R; et al. (medRxiv, 2025)

Towards "unmakable" psychedelics: SAR exploration of psilocin analogs obtained by a HATU-mediated amide coupling strategy - Stirn Judith; Berger Raphael; Hübner Harald; Gmeiner Peter; Klein Christian D. (European Journal of Medicinal Chemistry Reports, 2025)

[Psilocybin in the setting of treatment-resistant unipolar depression: A case report]. - Dumenil M; Cordova G; El-Hage W (L'Encephale, 2025)

Avoiding Stigma and Sensationalism in Therapeutic Psilocybin Communications: Considerations for Reaching Older Patients. - Gillespie CM; Bering JM (The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry, 2025)

Exploring the therapeutic potential of psychedelics in treating substance use disorders. - Li Y; Li H; Wang H; Wang X (Molecular psychiatry, 2025)

Between enhancement and risk: A critical review of psychedelic microdosing. - Totomanova I; Haijen ECHM; Hurks PPM; Ramaekers JG; Kuypers KPC (Current opinion in psychology, 2025)

Above the threshold, beyond the trip: the role of the 5-HT receptor in psychedelic-induced neuroplasticity and antidepressant effects. - Drewko AJ; Habets RLP; Brunt TM (Molecular psychiatry, 2025)

Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin. - Purple RJ; Gupta R; Thomas CW; Golden CT; Palomero-Gallagher N; Carhart-Harris R; Froudist-Walsh S; Jones MW (Molecular psychiatry, 2025)

Reply to Gattuso et al.: "Comments on 'Striking long-term beneficial effects of single-dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming' by Brownstien et al. (2024)". - Brownstien M; Lazar M; Botvinnik A; Pogodin I; Lifschytz T; Lerer B (Molecular psychiatry, 2025)

Correction: Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin. - Purple RJ; Gupta R; Thomas CW; Golden CT; Palomero-Gallagher N; Carhart-Harris R; Froudist-Walsh S; Jones MW (Molecular psychiatry, 2025)

Corrigendum to "Chronic psilocybin administration increases sociability and alters the gut microbiome in male wild-type mice but not in a preclinical model of obsessive-compulsive disorder" [Neuropharmacology 279 (2025) 110648]. - Gattuso JJ; Kong G; Bezcioglu B; Lu D; Ekwudo MN; Wilson C; Gubert C; Hannan AJ; Renoir T (Neuropharmacology, 2025)

Psilocybin inhibits formalin-induced nociception through 5-hydroxytryptamine 2A receptor in rats. - Inan S; Morris P; Rawls SM; Daws S (Behavioural pharmacology, 2025)

The transformational power of psychedelics: catalysts for creativity, consciousness, and mental health. - Du X; Liu J; Wang X (Molecular psychiatry, 2025)

Psilocybin as a fast-acting and long-lasting antidepressant for adolescence: Proposing NeuroD1 as a biomarker of its long-term plasticity. - García-Cabrerizo R; Beruete-Fresnillo I; Bergas-Cladera P; García-Fuster MJ (Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025)

Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis. - Højlund M; Kafali HY; Kırmızı B; Fusar-Poli P; Correll CU; Cortese S; Sabé M; Fiedorowicz J; Saraf G; Zein J; Berk M; Husain MI; et al. (European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology, 2025)

Psilocybin reduces comorbid chronic pain and depression in mice. - Ferreira J (Lab animal, 2025)

Sudden Loss of Consciousness Following Psilocybin Ingestion. - Downey AE; Tai ML; Bradley ER; Woolley JD (The American journal of psychiatry, 2025)

Acute Blockade of the Serotonin Transporter With Low Doses of Escitalopram Does Not Alter the Behavioural Responses to Acute Psilocybin. - Kleditzsch N; Gattuso JJ; Hannan AJ; Renoir T (The European journal of neuroscience, 2025)

Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment. - Modlin NL; Williamson V; Goodwin GM; Malievskaia E; Atli M; Elek Z; Gaillard A; Koelpin D; Cleare A; Agrawal M; Yehuda R; Kirlic N; et al. (EClinicalMedicine, 2025)

Using Insights from a Study of Psilocybin with Clergy to Advance Research on Psychedelics, Spirituality, and the Sacred: Commentary on Griffiths et al. (2025). - Palitsky R; Grant GH (Psychedelic medicine (New Rochelle, N.Y.), 2025)

Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions: The Great Promise of Psychedelics: Evolving Human Consciousness. - Brach T (Psychedelic medicine (New Rochelle, N.Y.), 2025)

Griffiths et al.'s Study of Psilocybin with Religious Professionals: A Theological Response from a Christian Perspective. - Lorenz J; Hawkins S; McCarthy B (Psychedelic medicine (New Rochelle, N.Y.), 2025)

Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions. - Griffiths RR; Jesse R; Richards WA; Johnson MW; Sepeda ND; Bossis AP; Ross S (Psychedelic medicine (New Rochelle, N.Y.), 2025)

Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions, by Griffiths et al. - de Wit H (Psychedelic medicine (New Rochelle, N.Y.), 2025)

Psilocybin, Spirituality, and the Potential for Personal Transformation: Commentary on Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions by Griffiths et al. - Pargament KI (Psychedelic medicine (New Rochelle, N.Y.), 2025)

Psychedelics as a Therapeutic Opportunity or Threat: A Narrative Review. - Liszka P; Ogórek A; Olejnik-Chlewicka KM; Puchalski K; Zasiadła M; Patrzykąt KM; Perediatkiewicz J; Urbański W; Łuczak PM; Brodowski J (Cureus, 2025)

A causal pluralist theory of the interaction of substance, set and setting in psychedelic experience - Julian Kiverstein; Hüseyin Beyköylü; Michiel van Elk (Philosophical Psychology, 2025)

Efficacy of psilocybin on death anxiety in terminal patients: a narrative review - Morris Lintong Barimbing; Dian Pritasari Jeger; Made Edwin Sridana (Progress in Palliative Care, 2025)

Persistent Altered States: Psychological Treatment of Psychedelic Adverse Effects - Bjørn Holmøy; Kristoffer Andreas Aamodt Andersen (Tidsskrift for Norsk psykologforening, 2025)

Psilocybin vs Ketamine for Alcohol Use Disorder - University of Iowa (ClinicalTrials.gov, 2025)

Digital Intervention for Psychedelic Preparation (DIPP): A Randomised Controlled Feasibility Trial Comparing Meditation and Music-Based Programs in Healthy Volunteers. - University College; London (ClinicalTrials.gov, 2025)

Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder - University of Texas at Austin (ClinicalTrials.gov, 2025)

A comparative assessment of the antidepressant efficacy of ketamine, psilocybin, and fluoxetine in a chronic stress model. - Domżalska M; Kwiatkowska J; Cichoń I; Sokołowska E (Scientific reports, 2025)

Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life - Charles S. Grob; M.D. (ClinicalTrials.gov, 2025)

Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community. - Kruger DJ; Mersereau G; Sullivan A; Barron J; Herberholz M; Pouyan N; Aday JS; Boehnke KF (Harm reduction journal, 2025)

Novel qNMR Method to Quantify Psilocybin and Psilocin in Psychedelic Mushrooms - Rodríguez Luisina; Morera Guillermo; Lupo Sandra; Davyt Danilo; Carrera Ignacio; Hernández Dossi Gonzalo (ACS Omega, 2025)

Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Disorders: A Scoping Review - J Pincombe; M.L. Williams; Sean Carruthers; Susan L. Rossell (Psychedelic Medicine, 2025)

Self-reported improvement in depression, anxiety, and substance use in Spanish-speakers after a memorable psychedelic experience - Stacey B. Armstrong; Meghan DellaCrosse; Jaime Fuentes-Balderrama; Rafaelle Lancelotta; Alan K. Davis (Psychedelics, 2025)

Interactions between psilocybin, LSD, and serotonergic antidepressants: A qualitative analysis of user reports - Holly Hepburn; Bart Ellenbroek; Jiun Youn (Psychedelics, 2025)

Exploring the first use of psychedelic macrodoses in Latin American adults: Sociodemographic profiles, consumption factors, and subjective experiences - Óscar Véliz-García; Marcos Domic-Siede (Journal of Psychedelic Studies, 2025)

Sex-specific role of the 5-HT receptor in psilocybin-induced extinction of opioid reward. - Jaster AM; Hadlock TM; Buzzi B; Maltman JL; Silva GM; Saha S; Koseli E; Pondelick AM; Thakur N; Zhang X; Li G; Ledesma-Corvi S; et al. (Nature communications, 2025)

Psilocybin and Chronic Pain: A New Perspective for Future Pain Therapists? - Natoli S; Cuomo A; Marchesini M; Luongo L; Lo Bianco G; Guardamagna VA; Yamaguchi S (Medical sciences (Basel, Switzerland), 2025)

Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans - University of Zurich (ClinicalTrials.gov, 2025)

A Double-blind, Phase II Feasibility Study to Assess the Safety and Efficacy of Psilocybin Microdosing Combined With Psychotherapy in Treatment-resistant Depression - Beersheva Mental Health Center (ClinicalTrials.gov, 2025)

Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients. - Beersheva Mental Health Center (ClinicalTrials.gov, 2025)

Synaptic priming: A framework for pharmacotherapy in depression. - Brown KA; Ajibola MI; Medeiros GC; Gould TD (Neuron, 2025)

Zalsupindole is a Nondissociative, Nonhallucinogenic Neuroplastogen with Therapeutic Effects Comparable to Ketamine and Psychedelics. - Agrawal R; Gillie D; Mungenast A; Chytil M; Engel S; Wu MC; Rasmussen K; Salinas E; Olson DE (ACS chemical neuroscience, 2025)

Pharmacotherapy to Prevent Alcohol Relapse in Alcohol-Associated Liver Disease. - Zhang W; Hwang SY; Luther J (Current gastroenterology reports, 2025)

Salience, sensemaking, and setting in psilocybin microdosing - Oblak; Aleš; Hudnik Korošec; Liam; Levačić; Anja; Elersič; Kristian; Pregelj; Peter; Bon; Jurij (Repository of the University of Ljubljana (University of Ljubljana), 2025)

Psychedelic Rejuvenation Hypothesis: A Framework for Cellular and Psychological Restoration - Montgomery Tony; Grant DeMond M. (Advance, 2025)

Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder - Peggy C Nopoulos (ClinicalTrials.gov, 2025)

Psilocybin Experiential Therapist Training: Insights from a World-First Study - Ioakimidis-MacDougall G; Gardner J; Liknaitzky P. (medRxiv, 2025)

Standardization of Psilocybin Dosing in a Natural Product-Based Retreat Setting: A Practical Method for Dose Quantification and Adjustment Across Sessions - Rosal SRP; Faber SC. (Research Square, 2025)

Unmixing the Psychedelic Connectome: Brain Network Traits of Psilocybin - Bhavaraju KP; Mason NL; Mallaroni P; Heinke D; Toennes SW; Ramaekers JG; Amico E. (bioRxiv, 2025)

Microdosing Psilocybin for Major Depressive Disorder: Study Protocol for a Phase II Double-Blind Placebo-Controlled Randomized Partial Crossover Trial - Zeina Beidas; Anya Ragnhildstveit; Adam Blackman; Thomas Anderson; Emily Fewster; Omer Syed; Valentyne Sobolenko; Ismail Kaan Kanca; Magdalena Jaglinska; Tatiana Son (PsyArXiv, 2025)

Spiritual dimension and psychedelic experiences: A phenomenological approach - Vargas Ibarra; Pablo (PhilArchive, 2025)

Qualitative insights into psilocybin and LSD experiences: Enhanced connection and emotion processing reported by Spanish-speaking survey respondents - Meghan DellaCrosse; Shoval Gilead; Rafael Lancelotta; Ana María Ortiz Bernal; Christopher Timmermann; Alan K. Davis (Psychedelics, 2025)

Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - 12-month data from an open-label pilot study. - Ellis S; Bostian C; Donnelly A; Feng W; Eisen K; Lean M; Conlan E; Ostacher M; Aaronson S; Suppes T (Journal of affective disorders, 2025)

Chronic psilocybin administration increases sociability and alters the gut microbiome in male wild-type mice but not in a preclinical model of obsessive-compulsive disorder. - Gattuso JJ; Kong G; Bezcioglu B; Lu D; Ekwudo MN; Wilson C; Gubert C; Hannan AJ; Renoir T (Neuropharmacology, 2025)

A Comparative Neurophenomenology of the Psychedelic State and Autism: Predictive Processing as a Unifying Lens - William Roseby; Catriona Osborn Moar (Psychoactives, 2025)

Toward Precision Psychedelic Therapies: Chemical, Computational, and Neuromodulatory Innovations. - Renner AC; Kargbo RB (ACS medicinal chemistry letters, 2025)

Stabilizing Psilocybin Pharmacology and Tuning Safety with Atypical Antipsychotic Cotherapy. - Renner AC; Kargbo RB (ACS medicinal chemistry letters, 2025)

Novel Psilocin Derivatives as Serotonergic Psychedelic Agents for Treating CNS Disorders - Sabnis Ram W. (ACS Medicinal Chemistry Letters, 2025)

Negative affective bias in depression following treatment with psilocybin or escitalopram - a secondary analysis from a randomized trial. - Martens MAG; Cunha BG; Erritzoe D; Nutt D; Carhart-Harris R; Harmer CJ (Translational psychiatry, 2025)

Correction: Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology - Kenneth Shinozuka; Katarina Jerotic; Pedro A. M. Mediano; A ZHAO; Katrin H. Preller; Robin Carhart-Harris; Morten L. Kringelbach (Translational Psychiatry, 2025)

Comparative Efficacy of Psilocybin and MDMA in PTSD Treatment: A Systematic Review of Long-Term Outcomes - Presley Aspen; Presley Pham; Jennifer Mitchell (Berkeley Scientific Journal, 2025)

Novel qNMR Methodto Quantify Psilocybin and Psilocinin Psychedelic Mushrooms - Luisina Rodríguez (12333694); Guillermo Morera (22593717); Sandra Lupo (22593720); Danilo Davyt (2738347); Ignacio Carrera (1677175); Gonzalo Hernández Dossi (22593723) (Figshare, 2025)

Dissimilar Reactions and Enzymes for Psilocybin Biosynthesis in Inocybe and Psilocybe Mushrooms. - Schäfer T; Haun F; Rupp B; Hoffmeister D (Angewandte Chemie (International ed. in English), 2025)

Psychedelic Augmentation of 12-Step Engagement: A Novel, Accessible Approach to Enhance Community-Based Recovery from Substance Use Disorders. - Mehtani NJ; Mian MN; Agin-Liebes G; Coker AR; Huebner C; Anderson BT; Mitchell JM (Journal of psychoactive drugs, 2025)

The Relationship Between Psychedelic Use and Alcohol Use Disorder in a Nationally Representative Sample. - Zech JM; Richard J; Jones GM (Journal of psychoactive drugs, 2025)

Ketamine and Psilocybin Differentially Impact Sensory Learning During the Mismatch Negativity - Allohverdi SG; Soltanzadeh M; Schmidt A; Charlton CE; Hauke DJ; Karvelis P; Vollenweider FX; Diaconescu AO. (bioRxiv, 2025)

Correction: Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice. - Fadahunsi N; Lund J; Breum AW; Mathiesen CV; Larsen IB; Knudsen GM; Klein AB; Clemmensen C (Translational psychiatry, 2025)

Divergent effects of ketamine and psilocybin on EEG power spectral density in a mismatch negativity paradigm - Milad Soltanzadeh; Zheng Wang; Shona G. Allohverdi; Colleen E. Charlton; André Schmidt; Franz Xaver Vollenweider; Andreea O. Diaconescu (Universität Zürich, ZORA, 2025)

Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder - Yale University (ClinicalTrials.gov, 2025)

A Phase 1/2 Study of a Group Model of Psilocybin-Assisted Therapy for Cancer-Related Anxiety in Patients With Metastatic Cancer - University of Washington (ClinicalTrials.gov, 2025)

Psilocybin reduces depressive-like behavior and improves cognition in healthy aging mice via epigenetic regulation of plasticity- and immune-related genes - Mennenga S; Hanson T; Semple M; Lifshitz D; Flores B; Balducci J; Harker S; Ford A; Lewis C. (Research Square, 2025)

Psilocybin and chronic neuropathic pain: a systematic review. - Jevotovsky DS; Chopra H; Pak DJ; Durbhakula S; Shustorovich A; Juneja T; Broachwala MY; AlFarra T; Silver C; Kreitzer G; Oreoluwa P; Weissman BB; et al. (Regional anesthesia and pain medicine, 2025)

Classic psychedelics may treat depressive disorders, but more evidence and legislative changes are required - Aisling McGuigan (Drugs & Therapy Perspectives, 2025)

Psilocybin-assisted physiotherapy for refractory motor functional neurological disorder: protocol for a randomised dose-comparison pilot study. - Bhagavan C; Bryson A; Carter O; Nielsen G; Berlowitz D; Issak S; Braat S; Zaloumis S; Attard Z; Eleftheriadis D; Oliver G; Mayne D; et al. (Acta neuropsychiatrica, 2025)

A Tragedy of Errors: The State of Psychedelic Research in the Treatment of Alcohol Use Disorder. - Srivastava AB; Gold MS (Brain sciences, 2025)

Reporting of side-effects in clinical trials of psilocybin-assisted psychotherapy for psychiatric conditions: systematic review. - Marinis J; Clarke ST; Guerin AA; Guastella AJ; Bedi G (BJPsych open, 2025)

Hormonal Influences on Psilocybin Responsivity Across the Female Lifespan: Toward Personalized Psychedelic-Assisted Therapy - Faith Ekoh; Shanice Rerrie; James Angud; Ersilia Mirabelli (Psychoactives, 2025)